Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Tumor necrosis factor-alpha Stories

2011-11-05 16:10:00

THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate (MTX) in Period one and were...

2011-10-04 09:27:14

The bacterium that causes tuberculosis has a unique molecule on its outer cell surface that blocks a key part of the body´s defense. New research suggests this represents a novel mechanism in the microbe´s evolving efforts to remain hidden from the human immune system. Researchers found that the TB bacterium has a molecule on its outer surface called lipomannan that can stop production of an important protein in the body´s immune cells that helps contain TB infection and...

2011-10-03 12:17:16

Alcohol is known to worsen the effects of disease, resulting in longer recovery period after trauma, injury or burns. It is also known to impair the anti-viral immune response, especially in the liver, including response against Hepatitis C (HCV) and HIV. New research published in BioMed Central's open access journal BMC Immunology shows that alcohol modulates the anti-viral and inflammatory functions of monocytes and that prolonged alcohol consumption has a double negative effect of reducing...

2011-10-03 09:48:00

DALLAS, Oct. 3, 2011 /PRNewswire-USNewswire/ -- Dr. Bruce A. Beutler, the new director of the Center for the Genetics of Host Defense at UT Southwestern Medical Center, today shared the Nobel Prize in Physiology or Medicine with two other scientists for their discoveries in how the immune system works. Dr. Beutler and Dr. Jules A. Hoffmann of Strasbourg University's Institut de Biologie Moleculaire et Cellulaire in France shared half the prize for their discovery of receptor proteins...

2011-09-28 08:20:01

Tokyo, Sept 28, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they will launch Humira(R) (adalimumab) Prefilled Syringe 20mg/0.4mL, a fully human anti-TNF-α monoclonal antibody for the treatment of polyarticular juvenile idiopathic arthritis (JIA) patients with low body weight, on September 29.Humira Prefilled Syringe 20mg/0.4mL received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare on July 1 of this...

2011-09-26 04:20:01

Tokyo, Sept 26, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have submitted an application in Japan seeking approval of inhibition of structural damage of joints in rheumatoid arthritis as an additional indication for Humira(R) (adalimumab; recombinant) Pre-filled Syringe 40 mg/0.8 mL, a fully human anti-TNF-alpha monoclonal antibody jointly developed by the two companies.The submission is based on the results of a double-blind study (HOPEFUL1...

2011-09-23 16:24:00

SILVER SPRING, Md., Sept. 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Remicade reduces signs and symptoms of UC and induces and maintains clinical remission in these patients. UC is a type of inflammatory bowel...

2011-09-08 09:46:14

Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta analysis Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases. Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of...

2011-08-10 05:11:00

MUMBAI, August 10, 2011 /PRNewswire/ -- - Revamilast is a PDE4 inhibitor, under development for Asthma, Rheumatoid Arthritis and other inflammatory disorders - The molecule successfully completed pre-clinical trials and Phase I studies - Phase I studies on healthy volunteers were carried out mainly in the UK - Glenmark has initiated global Phase IIb studies for both indications in Europe and...

2011-07-29 11:20:00

DALLAS, July 29, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia. "Eleven year-old Bo Anderson was prescribed Humira for a skin condition, psoriasis. After taking the drug for approximately ten months, Bo's parents noticed unusual bruising covering his body while on a family vacation," says drug defect attorney Andy Vickery. "Bo...